A Brief Online Training to Address Pharmacists' Willingness to Dispense Buprenorphine.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
medline:
10
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
aheadofprint
Résumé
The recent passage of the Mainstreaming Addiction Treatment (MAT) Act could increase the number of patients seeking to fill buprenorphine prescriptions at community pharmacies; however, multiple barriers limit community pharmacists' ability and willingness to dispense buprenorphine. We assess whether a brief online buprenorphine training program (Buprenorphine Understanding in the Pharmacy Environment) improves community pharmacists' outcomes, including willingness to dispense buprenorphine. A convenience sample of practicing community pharmacists participated in a 30-minute buprenorphine training. The training was codeveloped with pharmacy advisors and presented solutions to common buprenorphine dispensing barriers. Participants completed a pretest and posttest that assessed their buprenorphine knowledge (5 multiple-choice items based on training content), self-efficacy to engage in various buprenorphine-related behaviors (7 items), buprenorphine attitudes (8 items), and willingness to dispense buprenorphine to 4 different types of customers. Descriptive statistics were calculated, and paired-samples t tests were used to evaluate the impact of the training on pharmacist outcomes. Of 266 individuals who accessed the pretest, 104 responses were included in the analysis (response rate, 39%). Buprenorphine Understanding in the Pharmacy Environment improved pharmacists' mean buprenorphine knowledge scores (pretest, 2.2; posttest, 3.5; P < 0.001), all 7 self-efficacy items (all P < 0.001), mean buprenorphine attitudes (pretest, 3.1; posttest, 3.4; P < 0.001), and willingness to dispense to all four types of buprenorphine customers (all P < 0.01). A brief buprenorphine training increased pharmacists' willingness to dispense buprenorphine. Although generalizability of the results may be limited by use of a convenience sample, our pharmacist-oriented training showed promising results and may be an important step in increasing availability of buprenorphine in community pharmacies.
Sections du résumé
BACKGROUND
BACKGROUND
The recent passage of the Mainstreaming Addiction Treatment (MAT) Act could increase the number of patients seeking to fill buprenorphine prescriptions at community pharmacies; however, multiple barriers limit community pharmacists' ability and willingness to dispense buprenorphine. We assess whether a brief online buprenorphine training program (Buprenorphine Understanding in the Pharmacy Environment) improves community pharmacists' outcomes, including willingness to dispense buprenorphine.
METHODS
METHODS
A convenience sample of practicing community pharmacists participated in a 30-minute buprenorphine training. The training was codeveloped with pharmacy advisors and presented solutions to common buprenorphine dispensing barriers. Participants completed a pretest and posttest that assessed their buprenorphine knowledge (5 multiple-choice items based on training content), self-efficacy to engage in various buprenorphine-related behaviors (7 items), buprenorphine attitudes (8 items), and willingness to dispense buprenorphine to 4 different types of customers. Descriptive statistics were calculated, and paired-samples t tests were used to evaluate the impact of the training on pharmacist outcomes.
RESULTS
RESULTS
Of 266 individuals who accessed the pretest, 104 responses were included in the analysis (response rate, 39%). Buprenorphine Understanding in the Pharmacy Environment improved pharmacists' mean buprenorphine knowledge scores (pretest, 2.2; posttest, 3.5; P < 0.001), all 7 self-efficacy items (all P < 0.001), mean buprenorphine attitudes (pretest, 3.1; posttest, 3.4; P < 0.001), and willingness to dispense to all four types of buprenorphine customers (all P < 0.01).
CONCLUSIONS
CONCLUSIONS
A brief buprenorphine training increased pharmacists' willingness to dispense buprenorphine. Although generalizability of the results may be limited by use of a convenience sample, our pharmacist-oriented training showed promising results and may be an important step in increasing availability of buprenorphine in community pharmacies.
Identifiants
pubmed: 37948129
doi: 10.1097/ADM.0000000000001244
pii: 01271255-990000000-00246
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Society of Addiction Medicine.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Mainstreaming Addiction Treatment Act of 2021, S.445, 117th Congress (Sen. Hassan MW 2021). 2021. https://www.congress.gov/bill/117th-congress/senate-bill/445. Accessed May 23, 2023.
Carpenter D, Lambert KV, Harless JC, et al. North Carolina community pharmacists' buprenorphine dispensing practices and attitudes. J Am Pharm Assoc. 2022;62(5):1606–1614.
Ostrach B, Carpenter D, Cote LP. DEA disconnect leads to buprenorphine bottlenecks. J Addict Med. 2021;15(4):272–275.
Ostrach B, Potter R, Wilson CG, et al. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses. J Am Pharm Assoc (2003). 2022;62(2):588–597.e2.
Trull G, Major E, Harless C, et al. Rural community pharmacist willingness to dispense Suboxone®—a secret shopper investigation in south-central Appalachia. Explor Res Clin Soc Pharm. 2021;4:100082.
Hill LG, Light AE, Green TC, et al. Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists. J Am Pharm Assoc (2003). 2023;63(1):252–260.e6.
Hill LG, Loera LJ, Torrez SB, et al. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 2022;237:109518.
Ostrach B, Hill L, Carpenter D, et al. Addressing buprenorphine bottlenecks in the context of MAT act implementation: a shared responsibility. J Am Pharm Assoc. 2023;63(4):1044–1048.
Davis SA, Dryer R, Zule W, et al. A content review of buprenorphine training programs for pharmacists. Explor Res Clin Soc Pharm. 2022;6:100154.
Major EG, Wilson CG, Carpenter DM, et al. Factors in rural community buprenorphine dispensing. Explor Res Clin Soc Pharm. 2023;9:100204.